[F-18]-fluorodeoxy-D-glucose–positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults
dc.contributor.author | Hawkins, Douglas S. | en_US |
dc.contributor.author | Conrad, Ernest U. | en_US |
dc.contributor.author | Butrynski, James E. | en_US |
dc.contributor.author | Schuetze, Scott M. | en_US |
dc.contributor.author | Eary, Janet F. | en_US |
dc.date.accessioned | 2009-08-12T15:36:37Z | |
dc.date.available | 2010-10-05T18:27:30Z | en_US |
dc.date.issued | 2009-08-01 | en_US |
dc.identifier.citation | Hawkins, Douglas S.; Conrad, Ernest U.; Butrynski, James E.; Schuetze, Scott M.; Eary, Janet F. (2009). "[F-18]-fluorodeoxy-D-glucose–positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults." Cancer 115(15): 3519-3525. <http://hdl.handle.net/2027.42/63561> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/63561 | |
dc.description.abstract | BACKGROUND: Response to neoadjuvant chemotherapy is 1 of the most powerful prognostic factors for extremity osteosarcoma. [F-18]-fluorodeoxy-D-glucose–positron emission tomography (FDG-PET) is a noninvasive imaging modality that is used to predict histopathologic response. To determine the prognostic value of FDG-PET response for progression-free survival (PFS) in osteosarcoma, the authors of this report reviewed the University of Washington Medical Center experience. METHODS: Forty patients with extremity osteosarcoma were evaluated by FDG-PET. All patients received neoadjuvant and adjuvant chemotherapy. FDG-PET standard uptake values (SUVs) before neoadjuvant chemotherapy (SUV1) and after neoadjuvant chemotherapy (SUV2) were analyzed and correlated with histopathologic response. RESULTS: The median SUV1 was 6.8 (range, 3.0-24.1), the median SUV2 was 2.3 (range, 1.2-12.8), and the median SUV2 to SUV1 ratio (SUV2:1), was 0.36 (range, 0.12-1.10). A good FDG-PET response was defined as anSUV2 <2.5 or an SUV2:1 ≤0.5. FDG-PET responses according to SUV2 and SUV2:1 were concordant with histologic response in 58% and 68% of patients, respectively. SUV2 was associated with outcome (4-year PFS, 73% for SUV2 <2.5 vs 39% for SUV2 ≥2.5; P = .021). Both the initial disease stage and the histologic response were associated with outcome. CONCLUSIONS: FDG-PET imaging of extremity osteosarcoma was correlated only partially with a histologic response to neoadjuvant chemotherapy. An SUV2 <2.5 was associated with improved PFS. Future prospective studies are warranted to determine whether FDG-PET imaging may be used as a predictor of outcome independent of initial disease stage. Cancer 2009. © 2009 American Cancer Society. | en_US |
dc.format.extent | 166747 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | [F-18]-fluorodeoxy-D-glucose–positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Medical Oncology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Pediatrics, Seattle Children's Hospital, Seattle, Washington ; Fax: (206) 987-3946 ; Seattle Children's Hospital, 4800 Sandpoint Way, Mailstop: B-6553, Seattle, WA 98105-0371 | en_US |
dc.contributor.affiliationother | Departments of Orthopedics and Radiology, University of Washington Medical Center, Seattle, Washington | en_US |
dc.contributor.affiliationother | Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Departments of Orthopedics and Radiology, University of Washington Medical Center, Seattle, Washington | en_US |
dc.identifier.pmid | 19517457 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/63561/1/24421_ftp.pdf | |
dc.identifier.doi | 10.1002/cncr.24421 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.